Gonczi L, Bessissow T, Lakatos PL. Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”? World J Gastroenterol 2019; 25(41): 6172-6189 [PMID: 31749591 DOI: 10.3748/wjg.v25.i41.6172]
Corresponding Author of This Article
Peter Laszlo Lakatos, DSc, FRCP (C), MD, Full Professor, Staff Physician, Division of Gastroenterology, McGill University Health Centre, 1650 Cedar Avenue, Montreal H3G 1A4, Quebec, Canada. peter.lakatos@mcgill.ca
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 7, 2019; 25(41): 6172-6189 Published online Nov 7, 2019. doi: 10.3748/wjg.v25.i41.6172
Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?
Lorant Gonczi, Talat Bessissow, Peter Laszlo Lakatos
Lorant Gonczi, Peter Laszlo Lakatos, First Department of Medicine, Semmelweis University, Budapest H-1083, Hungary
Talat Bessissow, Peter Laszlo Lakatos, Division of Gastroenterology, McGill University Health Centre, Montreal H3G 1A4, Quebec, Canada
Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version; Bessissow T reviewed and language edited the submitted version of the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Peter Laszlo Lakatos, DSc, FRCP (C), MD, Full Professor, Staff Physician, Division of Gastroenterology, McGill University Health Centre, 1650 Cedar Avenue, Montreal H3G 1A4, Quebec, Canada. peter.lakatos@mcgill.ca
Telephone: +1-514-9341934 Fax: +1-514-9344452
Received: September 8, 2019 Peer-review started: September 8, 2019 First decision: September 19, 2019 Revised: September 26, 2019 Accepted: October 30, 2019 Article in press: October 30, 2019 Published online: November 7, 2019
Core Tip
Core tip: Inflammatory bowel diseases are chronic, progressive, immune-mediated disorders leading to disability and cumulative intestinal damage. There has been a major change in treatment paradigms favouring an early introduction of highly effective therapies, applying a treat-to-target approach to target composite clinical and endoscopical therapeutic endpoints and using close monitoring of objective markers of inflammation (with clinical, endoscopical and biomarker assessment) to direct therapeutic decisions until these goals are reached. Although several data support the benefit of ‘treat-to-target’ and “tight control” strategies so far, these approaches require further validation assessing long-term outcomes and more precise definition of therapeutic targets (for both endoscopic and biomarker monitoring).
